He had a recurrence on the skin of his left face in [**2112-12-16**], which on excisional biopsy showed clear cell neoplasm most consistent with metastatic renal cell carcinoma.
He was followed with surveillance imaging and on CT on [**2116-1-14**], torso revealed liver lesions consistent with metastatic disease.
He passed eligibility testing and began cycle 1 week 1 high-dose IL-2 on [**2116-3-9**] receiving 13 of 14 doses week 1 and 10 of 14 doses week 2.
Follow-up CTs revealed disease regression in the hepatic and right adrenal mets, and he was admitted for cycle 2 week 1 of therapy on [**2116-6-8**].
VITAL SIGNS:  97.2, 67, 16, 136/98.
ADMISSION LABS:  WBC 16.1, hemoglobin 12.3, hematocrit 35.5, platelet count 318,000, INR 1.2, BUN 16, creatinine 1.4, sodium 135, potassium 4.1, chloride 99, CO2 28, glucose 82, ALT 9, AST 19, CK 28, total bili 0.5, albumin 4.3, calcium 9.3, phosphorus 2.8, magnesium 2.2.
His admission weight was 74 kg and he received interleukin-2 600,000 international units per kilo equalling 44.6 million units IV q.
During this week he developed acute renal failure with a peak creatinine of 3.5 with associated oliguria and metabolic acidosis improved with bicarbonate replacement intravenously.
Electrolytes were monitored and repleted per protocol.
Strict urine output, serial creatinine bicarbonate levels were monitored.
daily, lorazepam 0.5 to 1 mg t.i.d.
FOLLOW-UP PLANS:  This patient will return to clinic in 4 weeks after CT scans to assess disease response.
